Jesús Díez-Manglano1,2,3,4, Mercedes Giménez-López5, Vanesa Garcés-Horna6, María Sevil-Puras6, Elena Castellar-Otín7, Paloma González-García8, Isabel Fiteni-Mera6, Teresa Morlanes-Navarro9. 1. Internal Medicine Department, Hospital Royo Villanova, Zaragoza, Spain. jdiez@aragon.es. 2. Comorbidity and Polypathology in Aragón Research Group, Instituto Aragonés de Ciencias de la Salud, Zaragoza, Spain. jdiez@aragon.es. 3. Departamento de Medicina, Dermatología y Psiquiatría, Universidad de Zaragoza, Zaragoza, Spain. jdiez@aragon.es. 4. , Duquesa Villahermosa n° 163, 8° D, 50009, Zaragoza, Spain. jdiez@aragon.es. 5. Geriatrics Department, Hospital San Juan de Dios, Zaragoza, Spain. 6. Internal Medicine Department, Hospital Royo Villanova, Zaragoza, Spain. 7. Internal Medicine Department, Hospital de Barbastro, Huesca, Spain. 8. Geriatrics Department, Hospital San José, Teruel, Spain. 9. Geriatrics Department, Hospital Nuestra Señora de Gracia, Zaragoza, Spain.
Abstract
PURPOSE: The purpose of this study was to determine whether excessive polypharmacy is associated with a higher survival rate in polypathological patients. PATIENTS AND METHODS: An observational, prospective, and multicenter study was carried out on those polypathological patients admitted to the internal medicine and acute geriatrics departments between March 1 and June 30, 2011. For each patient, data concerning age, sex, comorbidity, Barthel and Lawton-Brody indexes, Pfeiffer's questionnaire, socio-familial Gijon scale, delirium, number of drugs, and number of admissions during the previous year were gathered, and the PROFUND index was calculated. Polypharmacy was defined as the use of ≥ 5 drugs and excessive polypharmacy as the use of ≥ 10. A 1-year long follow-up was carried out. A logistic regression model was performed to analyze the association of variables with excessive polypharmacy and a Cox proportional hazard model to determine the association between polypharmacy and survival. RESULTS: We included 457 polypathological patients. Mean age was 81.0 (8.8) years and 54.5% were women. The mean number of drugs used was 8.2 (3.4). Excessive polypharmacy was directly associated with heart disease [hazard ratio (HR) 2.33 95% CI 1.40-3.87; p =0.001], respiratory disease [HR 1.87 95% CI 1.13-3.09; p = 0.01], peripheral artery disease/diabetes with retinopathy and/or neuropathy [HR 2.02 95% CI 1.17-3.50; p = 0.01], and the number of admissions during the previous year [HR 1.21 96%CI 1.01-1.44; p = 0.04]. It was inversely associated with delirium [HR 0.48 95% CI 0.25-0.91; p = 0.02]. There were no statistical differences regarding the probability of 1-year survival between patients with no polypharmacy, with simple polypharmacy, and with excessive polypharmacy (0.66, 0.60, and 0.57, respectively, p = 0.12). CONCLUSIONS: A greater use of drugs may not be harmful but is also not associated with a higher probability of survival in polypathological patients.
PURPOSE: The purpose of this study was to determine whether excessive polypharmacy is associated with a higher survival rate in polypathological patients. PATIENTS AND METHODS: An observational, prospective, and multicenter study was carried out on those polypathological patients admitted to the internal medicine and acute geriatrics departments between March 1 and June 30, 2011. For each patient, data concerning age, sex, comorbidity, Barthel and Lawton-Brody indexes, Pfeiffer's questionnaire, socio-familial Gijon scale, delirium, number of drugs, and number of admissions during the previous year were gathered, and the PROFUND index was calculated. Polypharmacy was defined as the use of ≥ 5 drugs and excessive polypharmacy as the use of ≥ 10. A 1-year long follow-up was carried out. A logistic regression model was performed to analyze the association of variables with excessive polypharmacy and a Cox proportional hazard model to determine the association between polypharmacy and survival. RESULTS: We included 457 polypathological patients. Mean age was 81.0 (8.8) years and 54.5% were women. The mean number of drugs used was 8.2 (3.4). Excessive polypharmacy was directly associated with heart disease [hazard ratio (HR) 2.33 95% CI 1.40-3.87; p =0.001], respiratory disease [HR 1.87 95% CI 1.13-3.09; p = 0.01], peripheral artery disease/diabetes with retinopathy and/or neuropathy [HR 2.02 95% CI 1.17-3.50; p = 0.01], and the number of admissions during the previous year [HR 1.21 96%CI 1.01-1.44; p = 0.04]. It was inversely associated with delirium [HR 0.48 95% CI 0.25-0.91; p = 0.02]. There were no statistical differences regarding the probability of 1-year survival between patients with no polypharmacy, with simple polypharmacy, and with excessive polypharmacy (0.66, 0.60, and 0.57, respectively, p = 0.12). CONCLUSIONS: A greater use of drugs may not be harmful but is also not associated with a higher probability of survival in polypathological patients.
Authors: M Bernabeu-Wittel; M Ollero-Baturone; L Moreno-Gaviño; B Barón-Franco; A Fuertes; J Murcia-Zaragoza; C Ramos-Cantos; A Alemán; A Fernández-Moyano Journal: Eur J Intern Med Date: 2010-12-22 Impact factor: 4.487
Authors: M Galván-Banqueri; L de la Higuera-Vila; M D Vega-Coca; M D Nieto Martín; C Pérez-Guerrero; B Santos-Ramos Journal: Eur J Intern Med Date: 2013-02-18 Impact factor: 4.487
Authors: Amaia Calderón-Larrañaga; Luis A Gimeno-Feliu; Francisca González-Rubio; Beatriz Poblador-Plou; María Lairla-San José; José M Abad-Díez; Antonio Poncel-Falcó; Alexandra Prados-Torres Journal: PLoS One Date: 2013-12-20 Impact factor: 3.240
Authors: Giorgina B Piccoli; Giorgio Grassi; Gianfranca Cabiddu; Marta Nazha; Simona Roggero; Irene Capizzi; Agostino De Pascale; Adriano M Priola; Cristina Di Vico; Stefania Maxia; Valentina Loi; Anna M Asunis; Antonello Pani; Andrea Veltri Journal: Rev Diabet Stud Date: 2015-08-10
Authors: Raquel Cadenas; María José Diez; Nélida Fernández; Juan José García; Ana M Sahagún; Matilde Sierra; Cristina López; Julen Susperregui; Raquel Díez Journal: Int J Environ Res Public Health Date: 2021-02-19 Impact factor: 3.390
Authors: Caroline Krüger; Ingmar Schäfer; Hendrik van den Bussche; Michael Baehr; Horst Bickel; Angela Fuchs; Jochen Gensichen; Wolfgang Maier; Steffi G Riedel-Heller; Hans-Helmut König; Anne Dahlhaus; Gerhard Schön; Siegfried Weyerer; Birgitt Wiese; Wolfgang von Renteln-Kruse; Claudia Langebrake; Martin Scherer Journal: Eur J Gen Pract Date: 2021-12 Impact factor: 1.904